Delenex Therapeutics AG – Product Pipeline Review

Global Markets Direct’s, ‘Delenex Therapeutics AG – Product Pipeline Review – 2016’, provides an overview of the Delenex Therapeutics AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Delenex Therapeutics AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Delenex Therapeutics AG

The report provides overview of Delenex Therapeutics AG including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Delenex Therapeutics AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Delenex Therapeutics AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Delenex Therapeutics AG’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Delenex Therapeutics AG

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Delenex Therapeutics AG’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Delenex Therapeutics AG Snapshot 5

Delenex Therapeutics AG Overview 5

Key Information 5

Key Facts 5

Delenex Therapeutics AG - Research and Development Overview 6

Key Therapeutic Areas 6

Delenex Therapeutics AG - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Delenex Therapeutics AG - Pipeline Products Glance 11

Delenex Therapeutics AG - Late Stage Pipeline Products 11

Phase III Products/Combination Treatment Modalities 11

Delenex Therapeutics AG - Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

Delenex Therapeutics AG - Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

Delenex Therapeutics AG - Drug Profiles 16

DLX-1008 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

DLX-105 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

DLX-2323 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

DLX-2681 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

DLX-2751 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

DLX-2882 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

DLX-2907 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

DLX-2909 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

DLX-2201 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Monoclonal Antibody Conjugate for Oncology and Inflammation 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibody for Oncology and Inflammation 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Delenex Therapeutics AG - Pipeline Analysis 29

Delenex Therapeutics AG - Pipeline Products by Target 29

Delenex Therapeutics AG - Pipeline Products by Route of Administration 30

Delenex Therapeutics AG - Pipeline Products by Molecule Type 31

Delenex Therapeutics AG - Pipeline Products by Mechanism of Action 32

Delenex Therapeutics AG - Recent Pipeline Updates 33

Delenex Therapeutics AG - Dormant Projects 34

Delenex Therapeutics AG - Locations And Subsidiaries 35

Head Office 35

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Tables

List of Tables

Delenex Therapeutics AG, Key Information 5

Delenex Therapeutics AG, Key Facts 5

Delenex Therapeutics AG – Pipeline by Indication, 2016 7

Delenex Therapeutics AG – Pipeline by Stage of Development, 2016 9

Delenex Therapeutics AG – Monotherapy Products in Pipeline, 2016 10

Delenex Therapeutics AG – Phase III, 2016 11

Delenex Therapeutics AG – Phase II, 2016 12

Delenex Therapeutics AG – Phase I, 2016 13

Delenex Therapeutics AG – Preclinical, 2016 14

Delenex Therapeutics AG – Discovery, 2016 15

Delenex Therapeutics AG – Pipeline by Target, 2016 29

Delenex Therapeutics AG – Pipeline by Route of Administration, 2016 30

Delenex Therapeutics AG – Pipeline by Molecule Type, 2016 31

Delenex Therapeutics AG – Pipeline Products by Mechanism of Action, 2016 32

Delenex Therapeutics AG – Recent Pipeline Updates, 2016 33

Delenex Therapeutics AG – Dormant Developmental Projects,2016 34

List of Figures

List of Figures

Delenex Therapeutics AG – Pipeline by Top 10 Indication, 2016 7

Delenex Therapeutics AG – Pipeline by Stage of Development, 2016 9

Delenex Therapeutics AG – Monotherapy Products in Pipeline, 2016 10

Delenex Therapeutics AG – Pipeline by Target, 2016 29

Delenex Therapeutics AG – Pipeline by Route of Administration, 2016 30

Delenex Therapeutics AG – Pipeline by Molecule Type, 2016 31

Delenex Therapeutics AG – Pipeline Products by Mechanism of Action, 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports